error
Divisa

SEVERE ASTHMA IN CHILDREN AND ADOLESCENTS

MECHANISMS AND MANAGEMENT

,
9783030274337 ::  SEVERE ASTHMA IN CHILDREN AND ADOLESCENTS
ISBN:

9783030274337

EditorialSPRINGER NATURE
Edició:
Idioma:INGLES
P.V.P.: 89,99 € + 4% IVA = 93,59 €
Dto 5% Estalvies 4,68 €
Import final iva incl. 88,91 €
Entrega en 15 dies
Altres versions :

<P>THIS BOOK PROVIDES READERS WITH A COMPREHENSIVE REVIEW OF SEVERE ASTHMA IN CHILDREN AND ADOLESCENTS, COVERING EPIDEMIOLOGY, GENETICS, RISK FACTORS, CO-MORBIDITIES, CLINICAL PRESENTATION, DIAGNOSIS AND TREATMENT. WRITTEN BY LEADERS IN THE FIELD, CHAPTER DISCUSSIONS DRAW ON THE MECHANISMS DRIVING THE DISEASE, GENETICS, MULTIDISCIPLINARY APPROACHES, IMMUNOMODULATORS, AND OTHER IMPORTANT ASPECTS IN THE MANAGEMENT OF THE DISEASE.&NBSP;</P><P><I>SEVERE ASTHMA IN CHILDREN AND ADOLESCENTS: MECHANISMS AND MANAGEMENT</I> IS DESIGNED TO BE A PRACTICAL GUIDE, OPENING WITH AN INTRODUCTION ON THE EPIDEMIOLOGY OF SEVERE CHILDHOOD ASTHMA, AS WELL AS A DISCUSSION OF SPECIAL CONSIDERATIONS OF THE DISEASE UNIQUE TO THE PRESCHOOL-AGED PATIENT.&NBSP; THE DISTINCTIONS BETWEEN THE DIAGNOSIS AND MANAGEMENT OF ASTHMA IN YOUNG CHILDREN OF VARIOUS AGES, AND SPECIFIC APPROACHES FOR THE ADOLESCENT WITH SEVERE ASTHMA, INCLUDING THE TRANSITION INTO ADULT CARE ARE THEN ADDRESSED. FINALLY, THE BOOK CLOSES WITH A DISCUSSION ON THE CURRENT STATE AND FUTURE AVENUES FOR SEVERE ASTHMA RESEARCH.&NBSP;</P><P><I>SEVERE ASTHMA IN CHILDREN AND ADOLESCENTS</I> IS AN INDISPENSABLE REFERENCE FOR THE HEALTHCARE PROFESSIONAL, FOR BASIC AND TRANSLATIONAL RESEARCHERS, AS WELL AS FOR STUDENTS, RESIDENTS AND FELLOWS.</P><DIV><BR></DIV><P></P><P></P>

<P>&NBSP;SECTION 1: GENERAL OVERVIEW</P><P>1.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; EPIDEMIOLOGY OF SEVERE ASTHMA: THIS CHAPTER WILL INCLUDE A DISCUSSION OF THE PREVALENCE OF ‘SEVERE ASTHMA’, HOW IT DIFFERS IN CHILDREN FROM ADULTS, NATURAL HISTORY FROM BIRTH COHORTS INTO ADOLESCENCE AND ADULT LIFE, IMPACT OF CHILDHOOD DISEASE ON ADULT FUNCTION AND COPD; ETC. </P><P>2.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; SPECIAL CONSIDERATIONS IN PRESCHOOL AGE: HIGHLIGHT THE IMPORTANCE OF THE PROBLEM, HOW PRESCHOOL DIFFERS FROM SCHOOL-AGE PRESENTATION AND NATURAL HISTORY, PATHOPHYSIOLOGY, VIRAL INDUCED WHEEZING, THE IMPACT OF ATOPY AND PREMATURITY; ETC. </P><P>&NBSP;</P><P>SECTION 2: DIAGNOSIS OF SEVERE ASTHMA</P>3.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; CONFIRMING THE DIAGNOSIS OF “SEVERE ASTHMA”: EVALUATION FOR “DIFFICULT TO TREAT” VS. SEVERE ASTHMA, EVALUATION OF STEROID RESPONSE, DISCUSSION OF ERS/ATS, GINA, AND NAEPP DEFINITIONS.<P></P><P>4.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; COMORBIDITIES OR “ASTHMA PLUS”: REVIEW OF HOW COMORBIDITIES MAY WORSEN ASTHMA, WITH EMPHASIS ON CHRONIC RHINOSINUSITIS, OBESITY, OBSTRUCTIVE SLEEP APNEA, GASTROESOPHAGEAL REFLUX DISEASE, ETC.</P><P>&NBSP;</P><P>SECTION 3: MANAGEMENT OF SEVERE ASTHMA</P><P>5.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; MULTIDISCIPLINARY MANAGEMENT: THE IMPORTANCE OF NON-PHARMACOLOGICAL MANAGEMENT INCLUDING LIFESTYLE MODIFICATION, SMOKING, POLLUTION, TRIGGER AVOIDANCE, ADHERENCE TO MEDICATION, NEED FOR SOCIAL SUPPORT, ETC.</P>6.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; STEPWISE PHARMACOLOGICAL APPROACH: REVIEW OF ATS/ERS, GINA, NAEPP STEPWISE APPROACH, INHALED STEROIDS, LABA, LAMA, THEOPHYLLINE, SYSTEMIC STEROIDS, LTRA, ETC.<P></P><P>7.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; IMMUNOTHERAPY AND IMMUNOMODULATORS: SCIT, SLIT, OMALIZUMAB, MEPOLIZUMAB, AND OTHER IMMUNOMODULATORS OR “BIOLOGICALS”.</P><P>8.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; SPECIAL CONSIDERATIONS FOR THE MANAGEMENT OF PRESCHOOL WHEEZE: DISCUSS THE ACUTE EPISODES AND MAINTENANCE THERAPY, ASSESSMENTS OF ETIOLOGY INFLAMMATION AND INFECTION TO DIRECT MANAGEMENT, ASTHMA PREDICTIVE INDEX, EARLY INTERVENTIONS AND DISEASE MODIFICATION.</P>9.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; MANAGEMENT OF SIDE EFFECTS AND COMPLICATIONS: IMPORTANCE OF PREVENTING AND MANAGING SIDE EFFECTS FROM MEDICATIONS, SUCH AS ADRENAL SUPPRESSION, BONE HEALTH, GROWTH ISSUES, ETC. WORKING WITH OTHER SUBSPECIALISTS. THE NEED FOR AN ANNUAL REVIEW.<P></P><P>10.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; MANAGEMENT OF ACUTE, SEVERE, LIFE-THREATENING EXACERBATIONS: ACUTE TREATMENT OPTIONS INCLUDING NON-INVASIVE AND INVASIVE VENTILATION. DISCUSSION OF THOSE PATIENTS WHO MAY DO NOT HAVE SEVERE CHRONIC IMPAIRMENT BUT THAT MOSTLY DO WELL AND THEN HAVE VERY ACUTE AND LIFE-THREATENING EXACERBATIONS.</P><P>11.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; ADOLESCENCE AND TRANSITION TO ADULTHOOD: IMPACT OF PUBERTY, MALES VS FEMALES, ISSUES IN ADOLESCENCE SUCH AS ADHERENCE, MEDICAL BELIEFS, IMPORTANCE OF A FORMAL APPROACH IN THE TRANSITION TO ADULT CARE, ASSESSMENT OF READINESS; ETC.</P><P>&NBSP;</P><P>SECTION 4: CURRENT AND FUTURE RESEARCH</P>12.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; BASIC MECHANISMS MEDIATING SEVERE PEDIATRIC ASTHMA: BASIC SCIENCE RESEARCH, ANIMAL MODELS, MOLECULAR STUDIES, POTENTIAL THERAPEUTIC AGENTS.<P></P><P>13.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; CLINICAL STUDIES AND CLINICAL TRIALS: PHYSIOLOGICAL ASSESSMENTS, BRONCHOSCOPIC STUDIES, PHENOTYPING/ENDOTYPING STUDIES, CLUSTER ANALYSES, BIOMARKERS, ETC.</P><P>14.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; GENOMICS AND PHARMACOGENOMICS: STUDIES INVOLVING GENETIC RISK/PREDISPOSITION, BIOMARKERS, PHARMACOGENETICS, TRANSCRIPTOMICS.</P><P>15.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; FUTURE DIRECTIONS: METABOLOMICS, PROTEOMICS, MICROBIOME; NEED FOR A UNIFIED APPROACH TO DEFINITION, MANAGEMENT, AND OUTCOMES TO ALLOW FOR INTERNATIONAL CLINICAL TRIALS.</P>16.&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP;&NBSP; POTENTIAL THERAPEUTIC AGENTS FROM ADULT TRIALS: EMERGING OPTIONS IN ADULTS THAT CAN BE EXTRAPOLATED TO PEDIATRICS, LAMA, IMMUNOSUPPRESSANTS, BRONCHIAL THERMOPLASTY, IMMUNOMODULATORS INCLUDING DUPILUMAB, BENRALIZUMAB, LEBRIKIZUMAB. BRONCHOSCOPIC-TAILORED TREATMENT, ANTIMICROBIALS, ETC.<P></P>

AL·LERGIA
PEDIATRIA
Llibres relacionats
ISBN: 9783030449667 PRACTICAL ASPECTS OF COSMETIC TESTINGPRACTICAL ASPECTS OF COSMETIC TESTING
9783030449667
Julio 2020

139.99€ S/I
132,99€ S/I

ISBN: 9783030212315 FOOD PROTEIN INDUCED ENTEROCOLITIS (FPIES)FOOD PROTEIN INDUCED ENTEROCOLITIS ...
9783030212315
Septiembre 2020

17,99€ S/I

ISBN: 9783030182847 PEDIATRIC ALLERGYPEDIATRIC ALLERGY
9783030182847
Agosto 2020

119.99€ S/I
113,99€ S/I

ISBN: 9783030503291 THE UNIFIED AIRWAYTHE UNIFIED AIRWAY
9783030503291
Agosto 2020

129.99€ S/I
123,49€ S/I

ISBN: 9783030517045 ATROPHIC RHINITISATROPHIC RHINITIS
9783030517045
Agosto 2020

139.99€ S/I
132,99€ S/I